Business

BrainStorm Cell Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

· GlobeWire Daily Business Desk · Source: www.prnewswire.com

2 min read

Key takeawaysBrainStorm Cell Therapeutics Inc. has released its financial results for the third quarter ended September 30, 2026, alongside a comprehensive corporate update detailing clinical, regulatory, and leadership developments.
BrainStorm Cell Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Original GlobeWire Daily editorial illustration — not an event photograph.

BrainStorm Cell Therapeutics Inc. has released its financial results for the third quarter ended September 30, 2026, alongside a comprehensive corporate update detailing clinical, regulatory, and leadership developments.

Financial Highlights

  • Cash Position: Cash, cash equivalents, and restricted cash stood at approximately $0.35 million as of September 30, 2026, compared to roughly $0.24 million on the same date in 2025.
  • Research and Development: Net R&D expenditures for the third quarter of 2026 were approximately $0.5 million, down from about $0.9 million in the corresponding period of 2025.
  • General and Administrative: G&A expenses totaled approximately $1.09 million for the quarter, compared to $1.15 million in the third quarter of 2025.
  • Net Loss: The net loss for the third quarter of 2026 narrowed to approximately $1.7 million, yielding a net loss per share of $(0.14), compared to a net loss of $2.1 million and $(0.14) per share in the third quarter of 2025.

Corporate and Clinical Updates

  • Phase 3b ENDURANCE Study: The company continues preparations to initiate the Phase 3b trial of NurOwn in earlier-stage ALS patients, operating under an FDA-agreed Special Protocol Assessment (SPA).
  • Leadership Changes: Professor Peter J. Pitts assumed the role of Executive Chairman and Chief Strategic Regulatory and Policy Officer, active in daily operations and regulatory strategy. Former Board Chairman Professor Jacob Frenkel transitioned to Senior Advisor.
  • Scientific Publications: BrainStorm's R&D team published preclinical findings regarding NurOwn-derived extracellular vesicles (ExMN) in *Stem Cell Research & Therapy*, indicating potential reductions in lung inflammation and fibrosis.
  • Industry Engagement: Executives participated in the 31st DUPHAT conference in Dubai, engaging with regional health regulators and commercial partners.

Practical Implications and Verification

Stakeholders and interested parties can review BrainStorm's regulatory filings, including Form 10-Q and Form 10-K reports, directly through the U.S. Securities and Exchange Commission (SEC) website at sec.gov to verify financial disclosures and ongoing corporate updates.

Share this article
Read the original source: BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Business Desk — AI-assisted news based on attributed published sources.

More to read